Lawrence Robbins, MD, Robbins Headache Clinic, Riverwoods, IL, discusses the safety profile of CGRPdirected antibodies in migraine and how clinical studies can be improved. After 3 years, 50,000 adverse events in migraine patients receiving CGRPdirected antibodies have been reported by the FDA. Many side effects of CGRP therapy, such as constipation and hypertension, have emerged after initial studies predicted a much milder safety profile. This may be explained by clinical trials often lacking a checklist for adverse events, which has been associated with missed side effects in 67% of patients. Studies are also often underpowered by cohort size and time. Overall, clinical trials need to be improved to more accurately represent potential side effects. The short and longterm sideeffects of CGRP antibodies in migraine need to be uncovered. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy) meeting.